Specialty Pharmacy Carve-Outs: The Volume Didn't Slow Down. It Was Redirected.
Specialty pharmacy volume — high-cost biologics, specialty injectables, limited distribution drugs — has been moving away from independent pharmacies for years through a mechanism that is structural, not competitive. PBMs and health plans designate specialty medications as "carve-out" drugs, meaning they are excluded from the standard pharmacy benefit and directed to PBM-owned or PBM-preferred specialty pharmacy operations. The designations are embedded in formulary design, covered under separate specialty benefit structures, and in many cases enforced through step therapy requirements and limited distribution agreements that independent pharmacies cannot participate in regardless of their dispensing capabilities.
The acceleration in 2026 is driven by two factors: the continued expansion of specialty tier drug lists — more drugs classified as specialty, fewer available through standard network pharmacies — and the integration of specialty pharmacy operations into vertically integrated PBM-insurer-specialty pharmacy structures that have an explicit financial incentive to keep specialty volume internal.
For an independent pharmacy whose patient panel includes patients on specialty medications — rheumatology patients on biologics, oncology support medications, multiple sclerosis drugs, high-cost diabetes medications now crossing specialty tier thresholds — the specialty carve-out represents a direct revenue extraction from your existing patient relationships. The patient is still yours clinically. The prescription is going somewhere else.
The mechanism works as follows: the patient's plan designates Drug X as specialty. Their benefit requires specialty drugs to be filled through the plan's preferred specialty pharmacy — typically a PBM-owned operation. The patient receives a letter or a call directing them to transfer their prescription. If they comply, the revenue leaves your pharmacy permanently. If they resist, the plan may impose cost-sharing penalties — higher copays, step therapy requirements, or prior authorization barriers — that make non-preferred dispensing economically painful for the patient.
The counter-strategy is not to fight the formulary designation. That is a regulatory battle you are not equipped to win at the individual pharmacy level. The counter-strategy is to capture the specialty volume that is still available — drugs that have not yet crossed the specialty tier threshold, limited distribution drugs where you can qualify as a dispensing pharmacy, and specialty medications covered under plans where your network agreement does not exclude specialty dispensing.
Two lists to build this month. First, identify every patient in your dispensing history from the last 12 months who was filling a medication that is now or soon will be classified as specialty tier by major Part D plans. Those are your at-risk patients. Contact them proactively — not to fight the plan's designation, but to ensure they have a clinical relationship with you strong enough that when the plan's letter arrives, they call you first. Second, identify which PBMs in your network have specialty pharmacy exclusions in your current agreement and which do not. The agreements where specialty dispensing is not explicitly excluded are your specialty revenue opportunity. Know which ones they are before the volume question becomes urgent.
Narrow Network Fights: The Counterintuitive Path to Winning
Narrow network exclusions — PBM and health plan decisions to exclude independent pharmacies from preferred or standard networks — continue to be among the most significant structural threats to independent pharmacy viability. The exclusion mechanism is straightforward: a plan designates a narrow network of preferred pharmacies, routes patients to those pharmacies through lower cost-sharing, and excludes independent pharmacies from preferred status through economic and operational criteria that large chains and mail-order operations meet more easily.
The conventional response to narrow network exclusion — regulatory advocacy, state legislation, legal challenge — is important at the industry level and largely unavailable as an individual pharmacy strategy. What is available, and what is being underutilized, is a set of network participation strategies that work precisely because they operate differently from how most independent pharmacy owners think about the problem.
The counterintuitive insight: the pharmacies winning narrow network inclusion fights are not winning on cost. They are winning on specificity. A PBM building a narrow network is making a coverage decision for a specific patient population in a specific geography with specific clinical needs. An independent pharmacy that can demonstrate that it serves a patient population the narrow network does not adequately cover — rural patients without convenient access to a preferred pharmacy, patients with complex medication regimens requiring clinical pharmacist engagement, patients in specific ethnic or linguistic communities where the chain pharmacy has no staff capability — is making a network participation argument that the PBM's actuarial model did not anticipate.
This argument requires documentation. Your patient population demographics, your languages spoken by staff, your distance from the nearest preferred network pharmacy for your patients, your clinical pharmacist credentials and consultative services — these are the inputs to a network inclusion appeal that is based on patient access rather than price competition. Network inclusion appeals based on patient access have a meaningful success rate. Network inclusion appeals based on "we deserve to be in the network" do not.
The 2027 network filings are being finalized now. If you have been excluded from a preferred network that is material to your revenue, this is the window to submit a network inclusion appeal — before the 2027 network is locked, not after it is announced. Contact the plan's network relations team, not the pharmacy help line. Request the criteria for preferred network inclusion. Ask specifically whether a patient access exception process exists. Document the request in writing. That documentation becomes the foundation of a formal appeal if the initial request is declined.
Gold Carding: The Reform That Helped the Easy Cases. Here's What It Missed.
Gold carding — the practice of exempting providers with strong prior authorization approval histories from the PA requirement for specific services — has been adopted by a growing number of states through legislation and by some payers voluntarily. The reform is real and meaningful: a provider whose prior authorization requests for a specific procedure are approved at a rate above a defined threshold no longer has to submit PA requests for that procedure. The administrative burden disappears for the covered service. That is a genuine improvement.
The limitation of gold carding as a systemic reform is that it addresses the straightforward cases — high-approval-rate procedures where PA was functioning primarily as a friction mechanism rather than a genuine clinical review — and leaves the hard cases untouched. The prior authorization burden that most significantly affects independent pharmacy revenue cycles is not on routinely approved services. It is on the services that are denied, appealed, and ultimately approved after weeks of administrative work. Gold carding does not reach those cases because those cases, by definition, do not have gold-card-qualifying approval rates.
For independent pharmacies, gold carding is most relevant in markets where your state has enacted gold carding legislation that applies to pharmacy benefit PA requirements — specifically for specialty medications where your dispensing approval history is strong. If your state has gold carding law and your PA approval rate for specific specialty medications qualifies, you may be able to request gold card status from plans that are required to grant it. Most independent pharmacy owners do not know whether their state has this requirement or whether their approval history qualifies.
The broader point: gold carding is one tool in a PA management strategy, not a replacement for one. The services most worth your time to gold card are the high-volume medications where PA submission is consuming staff time on approvals that are virtually certain — not the complex cases where the clinical review is genuinely contested.
Two actions for August. First, check whether your state has enacted gold carding legislation applicable to pharmacy PA requirements. If yes, request a copy of the qualifying criteria from each plan that imposes PA on your high-volume specialty medications. Second, pull your PA approval rate by medication and by plan for the last 12 months. Any medication where your approval rate exceeds 90 percent is a gold card candidate. Any plan where your overall PA approval rate exceeds 90 percent is a gold card conversation worth initiating. The administrative time you recover on those approvals can be redirected to the appeals that actually need clinical attention.